Rosmarinic Acid Intravitreal Implants: A New Therapeutic Approach for Ocular Neovascularization

Abstract

Rosmarinic acid, a plant-derived compound with antiangiogenic activity, can be applied for the treatment of ocular diseases related to neovascularization, such as diabetic retinopathy, macular edema, and age-related macular degeneration. These diseases represent the leading causes of blindness worldwide if they are not properly treated. Intravitreal devices allow for localized drug delivery to the posterior segment, increasing the drug bioavailability and promoting extended release, thus, reducing side effects and enhancing the patientʼs compliance to the treatment. In this work, rosmarinic acid-loaded poly lactic-co-glycolic acid intraocular implants were developed with a view for the treatment of ocular neovascularization. Physical-chemical, biocompatibility, and safety studies of the implants were carried out in vitro and in vivo as well as an evaluation of the antiangiogenic activity in a chorioallantoic membrane assay. Data obtained showed that rosmarinic acid released from the implants was quantified in the vitreous for 6 weeks, while when it was in the solution formulation, after 24 h, no drug was found in the vitreous. The delivery device did not show any sign of toxicity after clinical evaluation and in electroretinographic findings. Histological analysis showed normal eye tissue. Rosmarinic acid released from implants reduced 30% of new vesselʼs formation. The intravitreal implant successfully allowed for the prolonged release of rosmarinic acid, was safe to rabbits eyes, and demonstrated activity in vessel reduction, thus demonstrating potential in preventing neovascularization in ophthalmic diseases.

Key words

rosmarinic acid - implants - intravitreal - drug delivery - neovascularization - safety

Publikationsverlauf

Eingereicht: 13. Mai 2020

Angenommen nach Revision: 09. Juli 2020

Artikel online veröffentlicht:
14. August 2020

• References

• 1 Petersena M, Simmonds MSJ. Rosmarinic acid. Phytochemistry 2003; 62: 121-125
• 2 Amoah SKS, Sandjo LP, Kratz JM, Biavatti MW. Rosmarinic acid – pharmaceutical and clinical aspects. Planta Med 2016; 82: 388-406
• 3 Silva SB, Ferreira D, Pintado M, Sarmento B. Chitosan-based nanoparticles for rosmarinic acid ocular delivery – in vitro tests. Int J Biol Macromol 2016; 84: 112-120
• 4 Nunes S, Madureira R, Campos D, Sarmento B, Gomes AM, Pintado M, Reis F. Therapeutic and nutraceutical potential of rosmarinic acid – cytoprotective properties and pharmacokinetic profile. Crit Rev Food Sci Nutr 2017; 57: 1799-1806
• 5 Ferreira JLM, Chahud F, Ramalho LN, Modulo CM, Vieira LC, Reinach PS, Rodrigues MLV, Silva-Cunha A, Paula JS. Rosmarinic acid suppresses subconjunctival neovascularization in experimental glaucoma surgery. Curr Eye Res 2015; 40: 1134-1140
• 6 Kim JH, Lee BJ, Kim JH, Yu YS, Kim MY, Kim KW. Rosmarinic acid suppresses retinal neovascularization via cell cycle arrest with increase of p21WAF1 expression. Eur J Pharmacol 2009; 615: 150-154
• 7 Chen YY, Tsai CF, Tsai MC, Hsu YW, Lu FJ. Inhibitory effects of rosmarinic acid on pterygium epithelial cells through redox imbalance and induction of extrinsic and intrinsic apoptosis. Exp Eye Res 2017; 160: 96-105
• 8 Chemerovski-Glikman M, Mimouni M, Dagan Y, Haj E, Vainer I, Allon R, Blumenthal EZ, Adler-Abramovich L, Segal D, Gazit E, Zayit-Soudry S. Rosmarinic acid restores complete transparency of sonicated human cataract ex vivo and delays cataract formation in vivo . Sci Rep 2018; 8: 9341
• 9 Zych M, Wojnar W, Dudek S, Kaczmarczyk-Sedlak I. Rosmarinic and sinapic acids may increase the content of reduced glutathione in the lenses of estrogen-deficient rats. Nutrients 2019; 11: 803
• 10 Tsai CF, Wu JY, Hsu YW. Protective effects of Rosmarinic acid against selenite-induced cataract and oxidative damage in rats. Int J Med Sci 2019; 16: 729-740
• 11 Zhou YD, Yoshida S, Peng YQ, Kobayashi Y, Zhang LS, Tang LS. Diverse roles of macrophages in intraocular neovascular diseases: a review. Int J Ophthalmol 2017; 10: 1902-1908
• 12 Gariano RF, Gardner TW. Retinal angiogenesis in development and disease. Nature 2005; 438: 960-966
• 13 Bisht R, Mandal A, Jaiswal JK, Rupentha ID. Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases. WIREs Nanomed Nanobiotechno 2017; 10: 1-21
• 14 Lee SS, Hughes P, Ross AD, Robinson MR. Biodegradable implants for sustained drug release in the eye. Pharm Res 2010; 27: 2043-2053
• 15 Costa BL, Machado RR, Paiva MRB, Serakides R, Coelho MM, Silva-Cunha A, Fialho SL. Sirolimus-loaded biodegradable implants induce long lasting anti-inflammatory and antiangiogenic effects. J Drug Deliv Sci Technol 2018; 44: 373-379
• 16 Cunha RB, Siqueira RC, Messias A, Scott IU, Fialho SL, Cunha-Junior ADS, Jorge R. Safety and feasibility of a novel 25-gauge biodegradable implant of dexamethasone for treatment of macular edema associates with retinal vein occlusion. Retin Cases Brief Rep 2018; 12: 50-58
• 17 Rowe-Rendleman CL, Durazo SA, Kompella UB, Rittenhouse KD, Di Polo A, Weiner AL, Grossniklaus HE, Naash MI, Lewin AS, Horsager A, Edelhauser HF. Drug and gene delivery to the back of the eye: from bench to bedside. Invest Ophthalmol Vis Sci 2014; 55: 2714-2730
• 18 Tsai CH, Wang PY, Lin IC, Huang H, Liu GS, Tseng CL. Ocular drug delivery: role of degradable polymeric nanocarriers for ophthalmic application. Int J Mol Sci 2018; 19: 2830-2850
• 19 Fialho SL, Rego MGB, Cardillo JA, Siqueira RC, Jorge R, Silva-Cunha A. Biodegradable implants for intraocular drug delivery. Arq Bras Oftalmol 2003; 66: 891-896
• 20 Soares DCF, Oliveira DCP, Barcelos LS, Barbosa AS, Vieira LC, Townsend DM, Rubello D, Barros ALB, Duarte LP, Silva-Cunha A. Antiangiogenic activity of PLGA-Lupeol implants for potential intravitreal applications. Biomed Pharmacother 2017; 92: 394-402
• 21 Veras KS, Fachel FNS, Delagustin MG, Teixeira HF, Barcellos T, Henriques AT, Bassani VL, Koester LS. Complexation of rosmarinic acid with hydroxypropyl-β-cyclodextrin and methyl-β-cyclodextrin: Formation of 2: 1 complexes with improved antioxidant activity. J Mol Struct 2019; 1195: 582-590
• 22 Blasi P, Schoubben A, Giovagnoli S, Perioli L, Ricci M, Rossi C. Ketoprofen poly(lactide-co-glycolide) physical Interaction. AAPS PharmSciTech 2007; 8: E1-E8
• 23 Yang J, Lee CH, Park J, Seo S, Lim EK, Song YJ, Suh JS, Yoon HG, Huh YM, Haam S. Antibody conjugated magnetic PLGA nanoparticles for diagnosis and treatment of breast cancer. J Mater Chem 2007; 17: 2695-2699
• 24 Stehfest K, Boese M, Kerns G, Piry A, Wilhelm C. Fourier transform infrared spectroscopy as a new tool to determine rosmarinic acid in situ . J Plant Physiol 2004; 161: 151-156
• 25 Costa HS, Mansur AAP, Pereira MM, Mansur HS. Engineered hybrid scaffolds of poly(vinyl alcohol)/bioactive glass for potential bone engineering applications: synthesis, characterization, cytocompatibility, and degradation. J Nanomater 2012; 2012: 1-16
• 26 Chereddy KK, Payen VL, Préat V. PLGA polymer: From a classic drug carrier to a novel therapeutic activity contributor. J Control Release 2018; 289: 10-13
• 27 Fernandes-Cunha GM, Rezende CM, Mussel WN, da Silva GR, Elionai CDL, Yoshida MI, Fialho SL, Goes AM, Gomes DA, Vitor RWA, Silva-Cunha A. Anti-Toxoplasma activity and impact evaluation of lyophilization, hot molding process, and gamma-irradiation techniques on CLH-PLGA intravitreal implants. J Mater Sci Mater Med 2016; 27: 10
• 28 Fialho SL, Rêgo MB, Siqueira RC, Jorge R, Haddad A, Rodrigues AL, Maia-Filho A, Silva-Cunha A. Safety and pharmacokinetics of an intravitreal biodegradable implant of dexamethasone acetate in rabbit eyes. Curr Eye Res 2006; 31: 525-534
• 29 Bakri SJ, Thorne JE, Ho AC, Ehlers JP, Schoenberger SD, Yeh S, Kim SJ. Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration. Ophthalmology 2018; 126: 55-63
• 30 Kunou N, Ogura Y, Yasukawa T, Kimura H, Miyamoto H, Honda Y, Ikada Y. Long-term sustained release of ganciclovir from biodegradable scleral implant for the treatment of cytomegalovirus retinitis. J Control Release 2000; 68: 263-271
• 31 Cao W, Hu C, Wu L, Xu L, Jiang W. Rosmarinic acid inhibits inflammation and angiogenesis of hepatocellular carcinoma by suppression of NF-κB signaling in H22 tumor-bearing mice. J Pharmacol Sci 2016; 132: 131-137
• 32 Huang SS, Zheng RL. Rosmarinic acid inhibits angiogenesis and its mechanism of action in vitro . Cancer Lett 2006; 239: 271-280
• 33 Cabrera FJ, Wang DC, Reddy K, Achary G, Shin CS. Challenges and opportunities for drug delivery to the posterior of the eye. Drug Discov Today 2019; 24: 1679-1684
• 34 Quintana MLQ, Benedetto MM, Maldonado AC, Payer EV, Contin MA. Electroretinography: a biopotential to assess the function/dysfunction of the retina. J Phys Conf Ser 2016; 705: 012053
• 35 Chen J, Caspi RR. Clinical and functional Evaluation of ocular inflammatory Disease using the Model of experimental autoimmune Uveitis. In: Boyd A. ed. Immunological Tolerance Methods in molecular Biology. New York: Humana Press; 2019: 211-227
• 36 Marmor MF, Fulton AB, Holder GE, Miyake Y, Brigell M, Bach M. ISCEV Standard for full-field clinical electroretinography (2008 update). Doc Ophthalmol 2009; 118: 69-77